Table 5.
Comparison of baseline characteristics and changes in visual and morphologic outcomes in patients who required switchback to aflibercept after switching to faricimab versus those who did not.
| Switched Back Cases | Others | p-Value | |
|---|---|---|---|
| (n = 5) | (n = 38) | ||
| Age, years | 77.0 (73.0–82.0) | 80.0 (73.3–84.8) | 0.622 |
| Sex (female) | 2 (40.0%) | 14 (36.8%) | 1.000 |
| Subtype (PCV) | 5 (100.0%) | 24 (63.2%) | 0.156 |
| Lens (IOL) | 3 (60.0%) | 19 (50.0%) | 1.000 |
| History of PDT | 4 (80.0%) | 12 (31.6%) | 0.056 |
| Total no. of previous injections | 27.0 (23.0–38.0) | 34.5 (19.8–52.8) | 0.733 |
| Treatment interval, weeks | 5.0 (5.0–5.0) | 5.0 (4.0–6.0) | 0.583 |
| BCVA, logMAR | 0.16 (−0.08–0.22) | 0.13 (0.05–0.30) | 0.746 |
| Central retinal thickness, μm | 340.0 (320.0–416.0) | 283.5 (251.8–345.8) | 0.099 |
| Choroidal thickness, μm | 127.0 (102.0–295.0) | 161.0 (114.0–226.0) | 0.880 |
| Maximum PED, μm | 202.0 (179.0–318.0) | 190.5 (103.8–263.3) | 0.405 |
| Presence of SRH | 0 (0.0%) | 3 (7.9%) | 1.000 |
| Disrupted foveal ellipsoid zone | 2 (40.0%) | 19 (50.0%) | 1.000 |
Continuous variables are presented as medians and quartile ranges. p-values were calculated using the Mann–Whitney U test and Fisher’s exact test. BCVA, best-corrected visual acuity; IOL, intraocular lens; logMAR, logarithm of the minimum angle of resolution; PCV, polypoidal choroidal vasculopathy; PDT, photodynamic therapy; PED, pigment epithelium detachment; SRH, subretinal hemorrhage.